Treatment of multiple sclerosis with interferon beta-1b
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Reply from the Authors: It is impossible to compare the neutralizing antibody (NAB) response in the interferon beta-1b (IFNB-1b, Betaseron) trial1 with the NAB data in the Ares Serono trial or the trial by Jacobs et al.4 using interferon beta-1a (Rebif, Avonex), since neither of the two studies give sufficient details of assay methodology, assay sensitivity, or criteria of NAB positivity. In the Betaseron trial 11% of patients receiving placebo had NABs in at least one specimen, compared with 4% in …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Neutralizing antibodies and efficacy of interferon β-1aA 4-year controlled studyL. Kappos, M. Clanet, M. Sandberg-Wollheim et al.Neurology, July 11, 2005 -
ARTICLES
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bExperience during the first three years et al.Neurology, October 01, 1996 -
Articles
Effect of neutralizing antibodies on biomarker responses to interferon betaThe INSIGHT studyAndrew R. Pachner, John D. Warth, Amy Pace et al.Neurology, November 02, 2009 -
Articles
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosisR. A. Rudick, N. A. Simonian, J. A. Alam et al.Neurology, May 01, 1998